The Clinical Research Of Expression And Correlation Of Survivin And HSP70 In Bladder Transitional Cell Carcinoma

Objective:To explore the expression of Survivin and HSP70 in the bladder cancer,and the relevance of expression of Survivin and HSP70 , in search of early diagnosis and determine the prognostic value of tumor markers and take timely and reasonable methods of treatment to improve the overall survival rate of bladder cancer patients .Methods:Firstly, Using streptavidin-peroxidase(SP) method, we examined the expression of survivin and HSP70 in 48 samples bladder transitional cell cancer tissues and 13 samples normal bladder tissues, which are collected from the surgical resection confirmed by pathology, between October 2006 to August 2007 in The Second Affiliated Hospital of Hebei Medical University. Secondly we examined the expression of the two BTCC clinicopathological characteristics and the relationship between the two in the BTCC relevance of the expression of a statistical analysis.Then analysed by SPSS 13.0 statistical software package, withα= 0.05 as statistically significant test of the standard. Results:1. Among 48 samples BTCC tissues, Survivin protein did not express any normal bladder tissues in 13 samples, yet expressed positively in 37 samples, accounting for 77.08 percent (37/48), the difference was significant (P<0.01) . Positive rate of HSP70 is 15.38% (2/13) in 13 samples normal bladder tissues, and 27 samples of positive expressed in 48 samples BTCC tissues, accounting for 56.25% (27/48), the difference was significant (P <0.01).2. Rate of Survivin expression does not show a significant difference (P>0.05) for different ages, gender, size or the number of tumor. However, with increasing tumor grade, the ratio and intensity of Survivin expression will increase. The rate of Survivin expression were 42.86% (6/14), 88%(22/25), 100% (9/9). In I, III III-class BTCC, the difference was significant (P<0.01). With the increasing of BTCC clinical stage, the positive expression of Survivin was in a upward trend in the Ta-T₁ (superficial) and T₂-T₄ (invasive). Rate of Survivin expression were 60.00% (15/25), 95.65% (22/23), the difference was significant (P<0.01). Survivin protein in the early-onset group in the expression of 50.00% (9/18), and recurrence rate of the abnormal expression of 93.33 percent (28/30), so the difference of the two groups were significant (P<0.01).3. Rate of HSP70 expression did not show any significant difference (P>0.05) for different age, gender, size or the number of tumor. However, with increasing tumor grade, the ratio and intensity of HSP70 expression will increase. The rate of HSP70 expression was 28.57% (4/14), 64.00% (16/25), 77.78% (7/9). In I , II, III-class BTCC, the difference was significant (P <0.01). With the increase of BTCC clinical stage, the positive expression of HSP70 protein was a upward trend in the Ta-T1 (superficial) and T₂-T₄ (invasive). Rate of HSP70 expression was 36.00% (9/25), 78.26% (18/23), the difference was significant (P <0.01). HSP70 protein in the early-onset group in the abnormal expression of 27.78% (5/18), and recurrence rate of the abnormal expression of 73.33% (22/30), the difference was significant (P <0.01).4.Among 48 samples bladder transitional cell carcinoma, the positive co-expression of Survivin and HSP70 were 25 samples. The negative co-expression were 9 samples. The expression of Survivin was positively correlated with that of HSP70 (liner index of Pearson = 0.3457. P <0.05).Conclusion:1. Survivin and HSP70 were specifically expressed in bladder cancer tissues, involved in the occurrence and development of bladder cancer.2. Expressed with histological grade of bladder cancer, and increased clinical stage of tumor recurrence and upward, Survivin and HSP70 became an important indicator of the degree of malignancy in predicted bladder cancer.3.The expression of Survivin and HSP70 in the bladder cancer were positive correlated with the development of tumors in synergies. The expression of Survivin and HSP70 may become a better indicators about early diagnosis and prediction of recurrenc of bladder cancer, therefore, could be a new methods in targeted therapy bladder cancer.